Keck School of Medicine of USC
Department of Neurology
6th Annual Roxanna Todd Hodges Lectureship on Stroke Prevention & Education

Steven R. Levine, MD
Professor of Neurology and Emergency Medicine
Associate Dean, Clinical Research and Faculty Development
Vice-Chair, Department of Neurology
State University of New York (SUNY)

“Antiphospholipid Antibodies, Brain Infarcts, & Cognitive & Motor Decline in Aging (ABICMA): A Community-Based, Longitudinal, Clinical-Pathological Study”

Tuesday, July 25, 2017
12:00 PM – 1:00 PM
Herklotz Seminar Room (Room 112)
Zilkha Neurogenetic Institute

Summary - Antiphospholipid antibodies (aPL) are one of the more commonly detected findings in the diagnostic evaluation of coagulopathy associated with ischemic stroke in younger patients. We discuss aPL in the setting of pathologically proven cerebral infarction in older patients. Significance of mechanistic assays of a prothrombotic state associated with aPL will also be discussed.

Dr. Steve Levine is Professor of Neurology & Emergency Medicine at the State University of New York (SUNY). A research pioneer in the field of stroke, Dr. Levine was the Detroit site PI for the NIH-funded NINDS recombinant tissue plasminogen activator (rtPA) Stroke Trial that led to the FDA approval of the first treatment for acute ischemic stroke. His participation in NIH Funded research in acute and preventative clinical stroke trials for over 20 years puts him at the forefront of stroke research. His current areas of research include (a) proteins (antibodies) in the blood that promote clotting be a new risk factor for predicting recurrent stroke - antiphospholipid antibodies, (b) refining our understanding of the markers for risk and benefits from t-PA treatment for acute ischemic stroke, (c) pioneering the application of telemedicine (real time video-audio telecommunications) to stroke (“Telestroke”), and (d) Acute stroke clinical trials.